L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-life mobility insights from wearable sensors - Scorecard - MDSpire

L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-life mobility insights from wearable sensors

  • By

  • Alessandro Zampogna

  • Luigi Borzì

  • Domiziana Rinaldi

  • Gabriele Imbalzano

  • Martina Patera

  • Marco Falletti

  • Carlo Alberto Artusi

  • Edoardo Bianchini

  • Leonardo Lopiano

  • Gabriella Olmo

  • Antonio Suppa

  • June 15, 2026

  • 0 min

Share

Clinical Scorecard: Real-World Mobility Assessment Using Wearable Sensors in Advanced Parkinson’s Disease Patients Receiving L-Dopa/Carbidopa Intestinal Gel Infusion

At a Glance

CategoryDetail
Condition
Key MechanismsContinuous dopaminergic delivery through intrajejunal L-Dopa/Carbidopa intestinal gel (LCIG) infusion.
Target Population
Care Setting

Key Highlights

  • dyskinesia_duration

Guideline-Based Recommendations

Diagnosis

  • I
  • n
  • c
  • l
  • u
  • d
  • e
  • s
  • p
  • e
  • c
  • i
  • f
  • i
  • c
  • c
  • l
  • i
  • n
  • i
  • c
  • a
  • l
  • s
  • c
  • a
  • l
  • e
  • s
  • r
  • e
  • c
  • o
  • m
  • m
  • e
  • n
  • d
  • e
  • d
  • f
  • o
  • r
  • e
  • v
  • a
  • l
  • u
  • a
  • t
  • i
  • o
  • n
  • .

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Expand on criteria for patient selection for LCIG therapy.

        Clinical Best Practices

        • best_practices

        Related Resources & Content

        Original Source(s)

        L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-life mobility insights from wearable sensors

        • by Alessandro Zampogna, Luigi Borzì, Domiziana Rinaldi, Gabriele Imbalzano, Martina Patera, Marco Falletti, Carlo Alberto Artusi, Edoardo Bianchini, Leonardo Lopiano, Gabriella Olmo, Antonio Suppa

        • June 15, 2026

        Related Content

        Evidence for exponential progression in advanced Parkinson’s disease: retrospective analysis of a prospective cohort study

        Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

        Discrepancies in symptom concerns and burden from the perspectives of parkinson's disease patients, caregivers, and physicians